Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 13, 2008 - Issue 3
Submit an article Journal homepage
441
Views
38
CrossRef citations to date
0
Altmetric
Review

Emerging drugs for schizophrenia

Ofer Agid University of Toronto, Centre for Addiction and Mental Health (CAMH), Schizophrenia Program, Department of Psychiatry, 250 College Street, Toronto, Ontario M5T 1R8, Canada +1 416 535 8501, ext. 4862; +1 416 260 4197; [email protected]
, MD,
Shitij Kapur King's College, Institute of Psychiatry, Section of Schizophrenia, Imaging and Therapeutics, Department of Psychological Medicine, London, UK
, MBBS PhD FRCPC &
Gary Remington University of Toronto, Centre for Addiction and Mental Health (CAMH), Medication Assessment Program for Schizophrenia (MAPS) Clinic, Faculty of Medicine, Toronto, Ontario, Canada
, MD PhD FRCPC
Pages 479-495 | Published online: 02 Sep 2008

Bibliography

  • Freedman R. Schizophrenia. N Engl J Med 2003;349(18):1738-49
  • Bhugra D, Corridan B, Rudge S, et al. Early manifestations, personality traits and pathways into care for Asian and white first-onset cases of schizophrenia. Soc Psychiatry Psychiatr Epidemiol 1999;34(11):595-9
  • Kane JM. Schizophrenia. N Engl J Med 1996;334(1):34-41
  • Williams R, Dickson RA. Economics of schizophrenia. Can J Psychiatry 1995;40(7Suppl 2):S60-7
  • Carlsson A. Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatry 1978;135(2):165-73
  • Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 1975;188(4194):1217-9
  • Abi-Dargham A, Gil R, Krystal J, et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 1998;155(6):761-7
  • Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991;148(11):1474-86
  • Hietala J, Syvalahti E. Dopamine in schizophrenia. Ann Med 1996;28(6):557-61
  • Davis JM, Schaffer CB, Killian GA, et al. Important issues in the drug treatment of schizophrenia. Schizophr Bull 1980;6(1):70-87
  • Manchanda R, Norman RM, Malla AK, et al. Persistent psychoses in first episode patients. Schizophr Res 2005;80(1):113-6
  • Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996;153(3):321-30
  • Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord 2006;21(5):589-98
  • Idanpaan-Heikkila J, Alhava E, Olkinuora M, et al. Clozapine and agranulocytosis. Lancet 1975;2(7935):611
  • Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45(9):789-96
  • Tuunainen A, Wahlbeck K, Gilbody SM. Newer atypical antipsychotic medication versus clozapine for schizophrenia. Cochrane Database Syst Rev 2000;(2):CD000966
  • Iqbal MM, Rahman A, Husain Z, et al. Clozapine: a clinical review of adverse effects and management. Ann Clin Psychiatry 2003;15(1):33-48
  • Kapur S, Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 2001;50(11):873-83
  • Meltzer HY, Li Z, Kaneda Y, et al. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003;27(7):1159-72
  • Meltzer HY, Matsubara S, Lee JC. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989;25(3):390-2
  • Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 1989;251(1):238-46
  • Den Boer JA, Vahlne JO, Post P, et al. Ritanserin as add-on medication to neuroleptic therapy for patients with chronic or subchronic schizophrenia. Hum Psychopharmacol 2000;15(3):179-89
  • Offord SJ, Wong DF, Nyberg S. The role of positron emission tomography in the drug development of M100907, a putative antipsychotic with a novel mechanism of action. J Clin Pharmacol 1999;39(Suppl):17S-24S
  • Meltzer HY. An overview of the mechanism of action of clozapine. J Clin Psychiatry 1994;55(Suppl B):47-52
  • Remington G. Understanding antipsychotic “atypicality”: a clinical and pharmacological moving target. J Psychiatry Neurosci 2003;28(4):275-84
  • Kapur S, Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci 2000;25(2):161-6
  • Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 2001;158(3):360-9
  • Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002;47(1):27-38
  • Seeman P, Tallerico T. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry 1998;3(2):123-34
  • Pilowsky LS, Mulligan RS, Acton PD, et al. Limbic selectivity of clozapine. Lancet 1997;350(9076):490-1
  • Grunder G, Siessmeier T, Piel M, et al. Quantification of D2-like dopamine receptors in the human brain with 18F-desmethoxyfallypride. J Nucl Med 2003;44(1):109-16
  • Olsson H, Halldin C, Farde L. Differentiation of extrastriatal dopamine D2 receptor density and affinity in the human brain using PET. Neuroimage 2004;22(2):794-803
  • Mortimer AM, Lund CE, McKenna PJ. The positive:negative dichotomy in schizophrenia. Br J Psychiatry 1990;157:41-9
  • Lecrubier Y, Quintin P, Bouhassira M, et al. The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial. Acta Psychiatr Scand 2006;114(5):319-27
  • Purdon SE, Jones BD, Stip E, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry 2000;57(3):249-58
  • Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987;44(7):660-9
  • Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. Int J Neuropsychopharmacol 2004;7(Suppl 1):S1-5
  • Abi-Dargham A, Mawlawi O, Lombardo I, et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 2002;22(9):3708-19
  • Keltner NL, Johnson V. Biological perspectives. Aripiprazole: a third generation of antipsychotics begins? Perspect Psychiatr Care 2002;38(4):157-9
  • Rauly-Lestienne I, Boutet-Robinet E, Ailhaud MC et al. Differential profile of typical, atypical and third generation antipsychotics at human 5-HT(7a) receptors coupled to adenylyl cyclase: detection of agonist and inverse agonist properties. Naunyn Schmiedebergs Arch Pharmacol 2007;376(1-2):93-105
  • Hirose T, Kikuchi T. Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist. J Med Invest 2005;52(Suppl):284-90
  • Lawler CP, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999;20(6):612-27
  • Buckley PF. Broad therapeutic uses of atypical antipsychotic medications. Biol Psychiatry 2001;50(11):912-24
  • Kane JM, Leucht S, Carpenter D, et al. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 2003;64(Suppl 12):5-19
  • McEvoy J, Scheifler P, Frances A. Treatment of schizophrenia 1999. The expert consensus guideline series. J Clin Psychiatry 1999;60(Suppl 11):3-80
  • Aparasu RR, Bhatara V, Gupta S. US national trends in the use of antipsychotics during office visits, 1998 – 2002. Ann Clin Psychiatry 2005;17(3):147-52
  • IMS H. Atypical antipsychotics - generating evidence to inform policy and practice. Pharmaceutical Information Leading Products by Global Pharmaceutical Sales 2005. Available from: http://research.imshealth.com/research/research_schizophrenia.htm
  • Stagnitti MN. MEPS: Characteristics and Prescribed Medicines Files. Agency for Healthcare Research and Quality Household Component of the Medical Expenditure Panel Survey (MEPS-HC), U.S. Department of Health & Human Services. Available from: http://meps.ahrq.gov/mepsweb/data_fi les/publications/st144/stat144.pdf.
  • Aparasu RR, Bhatara V. Antipsychotic use and expenditure in the United States. Psychiatr Serv 2006;57(12):1693
  • Hamann J, Ruppert A, Auby P, et al. Antipsychotic prescribing patterns in Germany: a retrospective analysis using a large outpatient prescription database. Int Clin Psychopharmacol 2003;18(4):237-42
  • Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63(10):1079-87
  • Lieberman JA, Stroup TS, Mcevoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209-23
  • Leucht S, Barnes TR, Kissling W, et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003;160(7):1209-22
  • Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999;35(1):51-68
  • Leucht S, Wahlbeck K, Hamann J, et al. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003;361(9369):1581-9
  • Rosenheck R, Perlick D, Bingham S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003;290(20):2693-702
  • Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321(7273):1371-6
  • Alvarez-Jimenez M, Gonzalez-Blanch C, Crespo-Facorro B, et al. Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs 2008;22(7):547-62
  • Zipursky RB, Gu H, Green AI, et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry 2005;187:537-43
  • Kurtz MM, Moberg PJ, Ragland JD, et al. Symptoms versus neurocognitive test performance as predictors of psychosocial status in schizophrenia: a 1- and 4-year prospective study. Schizophr Bull 2005;31(1):167-74
  • Seeman P, Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987;1(2):133-52
  • Hyttel J, Arnt J, van den Berghe M. Selective dopamine D1 and D2 receptor antagonists. Psychopharmacol Ser 1989;7:109-22
  • Den Boer JA, van Megen HJ, Fleischhacker WW, et al. Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia. Psychopharmacology (Berl) 1995;121(3):317-22
  • Tauscher J, Hussain T, Agid O, et al. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. Am J Psychiatry 2004;161(9):1620-5
  • De Beaurepaire R, Labelle A, Naber D, et al. An open trial of the D1 antagonist SCH 39166 in six cases of acute psychotic states. Psychopharmacology (Berl) 1995;121(3):323-7
  • Karle J, Clemmesen L, Hansen L, et al. NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia. Psychopharmacology (Berl) 1995;121(3):328-9
  • Ahlenius S, Clozapine: dopamine D1 receptor agonism in the prefrontal cortex as the code to decipher a Rosetta stone of antipsychotic drugs. Pharmacol Toxicol 1999;84(5):193-6
  • Goldman-Rakic PS, Muly EC 3rd, Williams GV. D(1) receptors in prefrontal cells and circuits. Brain Res Brain Res Rev 2000;31(2-3):295-301
  • Okubo Y, Suhara T, Suzuki K, et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 1997;385(6617):634-6
  • Castner SA, Williams GV, Goldman-Rakic PS. Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science 2000;287(5460):2020-2
  • George MS, Molnar CE, Grenesko EL, et al. A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia. Schizophr Res 2007;93(1-3):42-50
  • Mu Q, Johnson K, Morgan PS, et al. A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia. Schizophr Res 2007;94(1-3):332-41
  • Diaz J, Pilon C, Le Foll B, et al. Dopamine D3 receptors expressed by all mesencephalic dopamine neurons. J Neurosci 2000;20(23):8677-84
  • Gurevich EV, Bordelon Y, Shapiro RM, et al. Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. Arch Gen Psychiatry 1997;54(3):225-32
  • Reavill C, Taylor SG, Wood MD, et al. Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. J Pharmacol Exp Ther 2000;294(3):1154-65
  • Southam E, Lloyd A, Jennings CA, et al. Effect of the selective dopamine D3 receptor antagonist SB-277011-A on regional c-Fos-like expression in rat forebrain. Brain Res 2007;1149:50-7
  • Lacroix LP, Hows ME, Shah AJ, et al. Selective antagonism at dopamine D3 receptors enhances monoaminergic and cholinergic neurotransmission in the rat anterior cingulate cortex. Neuropsychopharmacology 2003;28(5):839-49
  • Joyce JN, Millan MJ. Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov Today 2005;10(13):917-25
  • Lahti AC, Weiler M, Carlsson A, et al. Effects of the D3 and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophrenia. J Neural Transm 1998;105(6-7):719-34
  • Van Tol HH, Bunzow JR, Guan HC, et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991;350(6319):610-4
  • Kramer MS, Last B, Getson A, et al. The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group. Arch Gen Psychiatry 1997;54(6):567-72
  • Shahid M, Walker GB, Zorn SH, et al. Asenapine: a novel psychopharmacologicagent with a unique human receptor signature. J Psychopharmacol 2008
  • Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry 2007;68(10):1492-500
  • Newman-Tancredi A, Cussac D, Depoortere R. Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics. Curr Opin Investig Drugs 2007;8(7):539-54
  • Stone JM, Morrison PD, Pilowsky LS. Glutamate and dopamine dysregulation in schizophrenia – a synthesis and selective review. J Psychopharmacol 2007;21(4):440-52
  • Coyle JT. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 2006;26(4-6):365-84
  • Lahti AC, Weiler MA, Tamara Michaelidis BA, et al. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 2001;25(4):455-67
  • Olney JW, Newcomer JW, Farber NB. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 1999;33(6):523-33
  • Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148(10):1301-8
  • Tamminga CA, Holcomb HH, Gao XM, et al. Glutamate pharmacology and the treatment of schizophrenia: current status and future directions. Int Clin Psychopharmacol 1995;10(Suppl 3):29-37
  • Frankle WG, Lerma J, Laruelle M. The synaptic hypothesis of schizophrenia. Neuron 2003;39(2):205-16
  • Laruelle M, Frankle WG, Narendran R, et al. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation. Clin Ther 2005;27(Suppl A):S16-24
  • Patil ST, Zhang L, Martenyi F, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med 2007;13(9):1102-7
  • Goff DC, Tsai G, Levitt J, et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 1999;56(1):21-7
  • Heresco-Levy U, Javitt DC, Ermilov M, et al. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 1999;56(1):29-36
  • Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001;158(9):1367-77
  • Tuominen HJ, Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia. Cochrane Database Syst Rev 2006;(2):CD003730
  • Buchanan RW, Javitt DC, Marder SR, et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST). The efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 2007;164(10):1593-602
  • Rowley M, Bristow LJ, Hutson PH. Current and novel approaches to the drug treatment of schizophrenia. J Med Chem 2001;44(4):477-501
  • Cozzi A, AttuccI S, Peruginelli F, et al. Type 2 metabotropic glutamate (mGlu) receptors tonically inhibit transmitter release in rat caudate nucleus: in vivo studies with (2S,1′S,2′S,3′R)-2-(2′-carboxy-3′-phenylcyclopropyl)glycine, a new potent and selective antagonist. Eur J Neurosci 1997;9(7):1350-5
  • Svensson L, Zhang J, Johannessen K, et al. Effect of local infusion of glutamate analogues into the nucleus accumbens of rats: an electrochemical and behavioural study. Brain Res 1994;643(1-2):155-61
  • Xi ZX, Ramamoorthy S, Baker DA, et al. Modulation of group II metabotropic glutamate receptor signaling by chronic cocaine. J Pharmacol Exp Ther 2002;303(2):608-15
  • Hu G, Duffy P, Swanson C, et al. The regulation of dopamine transmission by metabotropic glutamate receptors. J Pharmacol Exp Ther 1999;289(1):412-6
  • Cartmell J, Monn JA, Schoepp DD. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J Pharmacol Exp Ther 1999;291(1):161-70
  • Rorick-Kehn LM, Johnson BG, Burkey JL, et al. Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039). J Pharmacol Exp Ther 2007;321(1):308-17
  • Schoepp DD. Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J Pharmacol Exp Ther 2001;299(1):12-20
  • Weinberger DR. Schizophrenia drug says goodbye to dopamine. Nat Med 2007;13(9):1018-9
  • Seeman P. Glutamate agonists for schizophrenia stimulate dopamine D2High receptors. Schizophr Res 2008;99(1-3):373-4
  • Kremer I, Vass A, Gorelik I, et al. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol Psychiatry 2004;56(6):441-6
  • Premkumar TS, Pick J. Lamotrigine for schizophrenia. Cochrane Database Syst Rev 2006;(4):CD005962
  • Moghaddam B, Adams B, Verma A, et al. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997;17(8):2921-7
  • Bubser M, Keseberg U, Notz PK, et al. Differential behavioural and neurochemical effects of competitive and non-competitive NMDA receptor antagonists in rats. Eur J Pharmacol 1992;229(1):75-82
  • Hampson RE, Rogers G, Lynch G, et al. Facilitative effects of the ampakine CX516 on short-term memory in rats: correlations with hippocampal neuronal activity. J Neurosci 1998;18(7):2748-63
  • Hampson RE, Rogers G, Lynch G, et al. Facilitative effects of the ampakine CX516 on short-term memory in rats: enhancement of delayed-nonmatch-to-sample performance. J Neurosci 1998;18(7):2740-7
  • Marenco S, Weinberger DR. Therapeutic potential of positive AMPA receptor modulators in the treatment of neuropsychiatric disorders. CNS Drugs 2006;20(3):173-85
  • Olsen CK, Kreilgaard M, Didriksen M. Positive modulation of glutamatergic receptors potentiates the suppressive effects of antipsychotics on conditioned avoidance responding in rats. Pharmacol Biochem Behav 2006;84(2):259-65
  • Goff DC, Lamberti JS, Leon AC, et al. A placebo-controlled add-on trial of the ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology 2007
  • Buchanan RW, Conley RR, Dickinson D, et al. Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry 2008;165(1):82-9
  • Betz H, Gomeza J, Armsen W, et al. Glycine transporters: essential regulators of synaptic transmission. Biochem Soc Trans 2006;34(Pt 1):55-8
  • Shim SS, Hammonds MD, Kee BS. Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site. Eur Arch Psychiatry Clin Neurosci 2007
  • Tsai G, Lane HY, Yang P, et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2004;55(5):452-6
  • Lane HY, Chang YC, Liu YC, et al. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry 2005;62(11):1196-204
  • Meltzer HY. What's atypical about atypical antipsychotic drugs? Curr Opin Pharmacol 2004;4(1):53-7
  • Weiner DM, Burstein ES, Nash N, et al. 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics. J Pharmacol Exp Ther 2001;299(1):268-76
  • ACADIA and A. Pharmaceuticals. Pimavanserin 2007. Available from: http://www.acadia-pharm.com/
  • Bantick RA, Deakin JF, Grasby PM. The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacol 2001;15(1):37-46
  • Mitchell ES, Neumaier JF. 5-HT6 receptors: a novel target for cognitive enhancement. Pharmacol Ther 2005;108(3):320-33
  • Roth BL, Craigo SC, Choudhary MS, et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994;268(3):1403-10
  • Roth BL, Hanizavareh SM, Blum AE. Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology (Berl) 2004;174(1):17-24
  • Goldman-Rakic P. Prefrontal cortical dysfunction in schizophrenia: the relevance of working memory, in psychopathology and the brain. In: Carroll B, Barrett J, editors. Raven Press: New York; 1991. p. 1-23
  • Goldman-Rakic PS, Lidow MS, Gallager DW. Overlap of dopaminergic, adrenergic, and serotoninergic receptors and complementarity of their subtypes in primate prefrontal cortex. J Neurosci 1990;10(7):2125-38
  • Arnsten AF, Goldman-Rakic PS. Alpha 2-adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. Science 1985;230(4731):1273-6
  • Arnsten AF, Cai JX, Goldman-Rakic PS. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes. J Neurosci 1988;8(11):4287-98
  • Friedman JI. Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology (Berl) 2004;174(1):45-53
  • Friedman JI, Adler DN, Temporini HD, et al. Guanfacine treatment of cognitive impairment in schizophrenia. Neuropsychopharmacology 2001;25(3):402-9
  • Weiland S, Bertrand D, Leonard S. Neuronal nicotinic acetylcholine receptors: from the gene to the disease. Behav Brain Res 2000;113(1-2):43-56
  • Martin LF, Kem WR, Freedman R. Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology (Berl) 2004;174(1):54-64
  • Adler LE, Olincy A, Waldo M, et al. Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull 1998;24(2):189-202
  • Ripoll N, Bronnec M, Bourin M. Nicotinic receptors and schizophrenia. Curr Med Res Opin 2004;20(7):1057-74
  • Jacobsen LK, D'souza DC, Mencl WE, et al. Nicotine effects on brain function and functional connectivity in schizophrenia. Biol Psychiatry 2004;55(8):850-8
  • Briggs CA, McKenna DG, Piattoni-Kaplan M. Human alpha 7 nicotinic acetylcholine receptor responses to novel ligands. Neuropharmacology 1995;34(6):583-90
  • Martin LF, Freedman R. Schizophrenia and the alpha7 nicotinic acetylcholine receptor. Int Rev Neurobiol 2007;78:225-46
  • Olincy A, Stevens KE. Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men. Biochem Pharmacol 2007;74(8):1192-201
  • Dyer MA, Freudenreich O, Culhane MA, et al. High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. Schizophr Res 2008
  • Lee SW, Lee JG, Lee BJ, et al. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia. Int Clin Psychopharmacol 2007;22(2):63-8
  • Dunbar G, Boeijinga PH, DemaziereS A, et al. Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers. Psychopharmacology (Berl) 2007;191(4):919-29
  • Shytle RD, Penny E, Silver AA, et al. Mecamylamine (Inversine): an old antihypertensive with new research directions. J Hum Hypertens 2002;16(7):453-7
  • Phillips JM, Ehrlichman RS, Siegel SJ. Mecamylamine blocks nicotine-induced enhancement of the P20 auditory event-related potential and evoked gamma. Neuroscience 2007;144(4):1314-23
  • Hays JT, Ebbert JO, Sood A. Efficacy and safety of varenicline for smoking cessation. Am J Med 2008;121(4 Suppl 1):S32-42
  • Dean B, Mcleod M, Keriakous D, et al. Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 2002;7(10):1083-91
  • Anagnostaras SG, Murphy GG, Hamilton SE, et al. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci 2003;6(1):51-8
  • Friedman JI, Temporini H, Davis KL. Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol Psychiatry 1999;45(1):1-16
  • Dean B, Bymaster FP, Scarr E. Muscarinic receptors in schizophrenia. Curr Mol Med 2003;3(5):419-26
  • Bodick NC, Offen WW, Levey AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 1997;54(4):465-73
  • Tecle H, Schwarz RD, Barrett SD, et al. CI-1017, a functionally M1-selective muscarinic agonist: design, synthesis, and preclinical pharmacology. Pharm Acta Helv 2000;74(2-3):141-8
  • Kennett GA, Wood MD, Bright F, et al. SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology 1997;36(4-5):609-20
  • Lameh J, Burstein ES, Taylor E, et al. Pharmacology of N-desmethylclozapine. Pharmacol Ther 2007;115(2):223-31
  • Sporn AL, Vermani A, Greenstein DK, et al. Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. J Am Acad Child Adolesc Psychiatry 2007;46(10):1349-56
  • Volpicelli LA, Levey AI. Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus. Prog Brain Res 2004;145:59-66
  • Laviolette SR, Grace AA. The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction. Cell Mol Life Sci 2006;63(14):1597-613
  • Leweke FM, Giuffrida A, Wurster U, et al. Elevated endogenous cannabinoids in schizophrenia. Neuroreport 1999;10(8):1665-9
  • Koethe D, Llenos IC, Dulay JR, et al. Expression of CB(1) cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. J Neural Transm 2007;114(8):1055-63
  • Newell KA, Deng C, Huang XF. Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Exp Brain Res 2006;172(4):556-60
  • Johns A. Psychiatric effects of cannabis. Br J Psychiatry 2001;178:116-22
  • Martinez-Arevalo MJ, Calcedo-Ordonez A, Varo-Prieto JR. Cannabis consumption as a prognostic factor in schizophrenia. Br J Psychiatry 1994;164(5):679-81
  • Negrete JC. Cannabis and schizophrenia. Br J Addict 1989;84(4):349-51
  • Haller J, Szirmai M, Varga B, et al. Cannabinoid CB1 receptor dependent effects of the NMDA antagonist phencyclidine in the social withdrawal model of schizophrenia. Behav Pharmacol 2005;16(5-6):415-22
  • Jarbe TU, Ross T, Dipatrizio NV, et al. Effects of the CB1R agonist WIN-55,212-2 and the CB1R antagonists SR-141716 and AM-1387: open-field examination in rats. Pharmacol Biochem Behav 2006;85(1):243-52
  • Poncelet M, Barnouin MC, Breliere JC, et al. Blockade of cannabinoid (CB1) receptors by 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils. Psychopharmacology (Berl) 1999;144(2):144-50
  • Meltzer HY, Arvanitis L, Bauer D, et al. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 2004;161(6):975-84
  • Spooren W, Riemer C, Meltzer H. Opinion: NK3 receptor antagonists: the next generation of antipsychotics? Nat Rev Drug Discov 2005;4(12):967-75
  • Maggi CA. The mammalian tachykinin receptors. Gen Pharmacol 1995;26(5):911-44
  • Marco N, Thirion A, Mons G, et al. Activation of dopaminergic and cholinergic neurotransmission by tachykinin NK3 receptor stimulation: an in vivo microdialysis approach in guinea pig. Neuropeptides 1998;32(5):481-8
  • Maino K, Gruber R, Riedel M, et al. T- and B-lymphocytes in patients with schizophrenia in acute psychotic episode and the course of the treatment. Psychiatry Res 2007;152(2-3):173-80
  • Maes M, Bocchio Chiavetto L, Bignotti S, et al. Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. Eur Neuropsychopharmacol 2000;10(2):119-24
  • Muller N, Schwarz MJ. COX-2 inhibition in schizophrenia and major depression. Curr Pharm Des 2008;14(14):1452-65
  • Muller N, Schwarz M. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotox Res 2006;10(2):131-48
  • Miller CL, Llenos IC, Cwik M, et al. Alterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder. Neurochem Int 2008;52(6):1297-303
  • Akhondzadeh S, Tabatabaee M, Amini H,et al. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res 2007;90(1-3):179-85
  • Tulloch AD, Fearon P, David AS. Social outcomes in schizophrenia: from description to action. Curr Opin Psychiatry 2006;19(2):140-4
  • NIH and N.I.o. Health. ClinicalTrials.gov 2007. Available from: http://clinicaltrials.gov
  • SRF and S.R. Forum, Drugs in Clinical Trials for Schizophrenia; 2007
  • Laughren T, Levin R. Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim. Schizophr Bull 2006;32(2):220-2
  • Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2003;27(7):1081-90
  • Miyamoto S, Duncan GE, Marx CE, et al. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005;10(1):79-104
  • Arranz MJ, Kerwin RW. Advances in the pharmacogenetic prediction of antipsychotic response. Toxicology 2003;192(1):33-5
  • Arranz MJ, Munro J, Birkett J, et al. Pharmacogenetic prediction of clozapine response. Lancet 2000;355(9215):1615-6
  • Norton N, Williams HJ, Owen MJ. An update on the genetics of schizophrenia. Curr Opin Psychiatry 2006;19(2):158-64
  • Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 2007;12(8):707-47

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.